| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.9 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.0084 | 0.9 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | -0.028 | 0.9 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | 0.0086 | 0.9 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.0055 | 0.9 |